Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BIOCRYST PHARMACEUTICALS INC

Get SEC filing alerts via email and in your feed for BIOCRYST PHARMACEUTICALS INC

BCRX

BIOCRYST PHARMACEUTICALS INC

About BIOCRYST PHARMACEUTICALS INC

BioCryst Pharmaceuticals, Inc. is a global biotechnology company specializing in structure-guided drug design to develop oral small-molecule and injectable protein therapeutics for rare diseases. Its key products include ORLADEYO, an oral treatment for hereditary angioedema, and peramivir injection for influenza. BioCryst targets niche markets with high unmet medical needs, leveraging proprietary technology and strategic partnerships to advance drug candidates from discovery through commercialization.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BIOCRYST PHARMACEUTICALS INC

1
1
BIOCRYST PHARMACEUTICALS INC BioCryst Pharmaceuticals Reports $156.4M Revenue in Q1 2026, Faces $721.8M Net Loss

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
BIOCRYST PHARMACEUTICALS INC BioCryst Pharmaceuticals Reports $263.9 Million Net Income, Achieves First Annual Profitability

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
BIOCRYST PHARMACEUTICALS INC BioCryst Pharmaceuticals Reports 36% Revenue Growth and Net Income Turnaround in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BIOCRYST PHARMACEUTICALS INC BioCryst Pharmaceuticals Reports 49.4% Revenue Growth and Net Income Turnaround in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BIOCRYST PHARMACEUTICALS INC BioCryst Pharmaceuticals Reports 57% Revenue Growth to $145.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BIOCRYST PHARMACEUTICALS INC BioCryst Pharmaceuticals Reports Revenue Growth, Reduced Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments